Creative Planning Aerie Pharmaceuticals Inc Transaction History

Creative Planning

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 29, 2021	SELL	$9.12 - $14.49 $200,639 - $318,780	-22,000 Closed	0 $0
Q3 2020 Nov 05, 2020	SELL	$10.46 - $14.46 $89,956 - $124,356	-8,600 Reduced 28.1%	22,000 $259,000
Q4 2019 Jan 30, 2020	BUY	$17.72 - $25.1 $15,239 - $21,586	860 Added 2.89%	30,600 $740,000
Q3 2019 Nov 01, 2019	SELL	$18.41 - $28.0 $11,046 - $16,800	-600 Reduced 1.98%	29,740 $572,000
Q2 2019 Jul 26, 2019	BUY	$28.97 - $48.21 $109,651 - $182,474	3,785 Added 14.25%	30,340 $897,000
Q1 2019 Apr 24, 2019	BUY	$36.32 - $49.25 $964,477 - $1.31 Million	26,555 New	26,555 $1.26 Million
Q3 2018 Oct 25, 2018	SELL	$56.15 - $73.9 $235,830 - $310,380	-4,200 Closed	0 $0
Q1 2018 Apr 18, 2018	BUY	$51.15 - $61.0 $30,690 - $36,600	600 Added 16.67%	4,200 $228,000
Q4 2017 Jan 17, 2018	SELL	$50.85 - $65.1 $30,510 - $39,060	-600 Reduced 14.29%	3,600 $215,000
Q3 2017 Oct 17, 2017	BUY	$48.6 - $60.1 $204,120 - $252,420	4,200	4,200 $204,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.